Mylan NV's proposed biosimilar of Genentech Inc.'s Herceptin (trastuzumab), appears to have met all of FDA's requirements for approval, but the sponsor still may have to answer questions about its development partner's manufacturing issues.
FDA's overall conclusion was that the totality of evidence suggests that MYL-1401O is highly similar to US-approved Herceptin notwithstanding minor...





